To explore the feasibility of designing vaccination protocols in acute leukemia patients with cytokine gene-transduced leukemic cells, we studied in vitro the growth potential of human leukemic cells transduced with the interleukin-2 (IL-2), IL-7, or IL-7 plus IL-2 genes, as well as the capacity of generating both autologous and allogeneic cytotoxic lymphocytes directed against the parental cells. A lymphoblastic T-cell line, ST4, obtained from a patient in long-lasting complete remission, was retrovirally engineered with the IL-2, IL-7, and IL-7 plus IL-2 genes; in addition, clones releasing different amounts of the cytokines were obtained by limiting dilution. Mixed lymphocyte-tumor cultures (MLTCs) were set up with parental or transduced leukemic cells as stimulators and with autologous or allogeneic lymphocytes as responders. When nonirradiated ST4 parental cells or clones producing Ͻ50 international units (IU)/mL/10 6 cells/72 hours of IL-2 were used as stimulators, leukemic overgrowth was observed in MLTCs within 16 days of culture. When clones producing Ͼ80 IU/mL/10 6 cells/72 hours of IL-2 were used as stimulators, the proliferation of leukemic cells was blocked and the transduced leukemic cells were completely cleared from the cultures by day 16; repeated restimulations with IL-2-producing leukemic cells were required to sustain long-term lymphocyte survival. On the contrary, when IL-7-or IL-7-IL-2-producing cells were used as stimulators, only a delay in leukemic cell overgrowth was observed, and lymphocytes were completely cleared from the cultures after day 60. IL-7 production by the different clones ranged between 11 and 36 ng/mL/10 6 cells/72 hours, whereas the highest IL-2-producing IL-7-IL-2 clone released 50 IU/mL/10 6 cells/72 hours of IL-2. When the stimulator efficacy of the highest IL-2-producing clone (ST4/IL-2#A7) was compared with that of exogenous IL-2 plus parental cells, a 7-fold higher amount of exogenous IL-2 was required to achieve the same results obtained with IL-2-producing leukemic cells. Autologous and allogeneic long-term MLTCs (up to 35 days) with ST4/IL-2#A7 as the stimulator were capable of generating cytotoxic effectors equally endowed with both major histocompatibility complex (MHC) class I-unrestricted and -restricted activity against parental ST4 cells. By day 18 of both autologous and allogeneic cultures, a substantial proportion of CD56 ϩ cells was consistently recorded; this was coupled to a predominantly MHC-unrestricted cytotoxic activity directed against parental ST4 cells. CD56 ϩ cells decreased considerably at the end of the different MLTCs, together with the unrestricted cytotoxic activity. At this time, Ͼ50% of the cells were CD8 ϩ , and 55% of the activity could be blocked by an anti-MHC class I monoclonal antibody. The results of this study demonstrate that IL-2 gene-transduced human acute leukemia cells cocultured with both autologous and allogeneic lymphocytes are capable of inducing a strong MHC-unrestricted anti-leukemic activity and subsequently "educating" MHC class I-restricted anti-leukemic effectors. The evidence that the immunogenic potential of human leukemic blasts can be boosted after transfer of the IL-2 gene suggests that the possibility of using leukemic cells engineered to release IL-2 as a therapeutic vaccine needs to be explored further.
I
nterleukin-2 (IL-2)-based immunotherapeutic protocols may represent a therapeutic option for a proportion of acute leukemia patients. [1] [2] [3] [4] Clinical responses have, in fact, been reported in advanced stage acute myeloid leukemia patients with a limited proportion of residual bone marrow blasts. 2, 5 Despite these encouraging results and despite the knowledge that the immune compartment of the host may be activated in the IL-2-treated leukemic patients, 6, 7 it is still uncertain which lymphocyte subset, if any, may be responsible for the clinical results observed, and whether the generation of the cytotoxic response is mediated by antigenic structures present on the leukemic cells. Indirect evidence that this may be the case stems from studies carried out mostly in chronic myeloid leukemia 8, 9 and also in acute promyelocytic leukemia, 10 two conditions with a specific fusion protein that originates from a well-defined and characteristic molecular abnormality.
The possibility of introducing foreign DNA into the genome of neoplastic cells by gene transfer technologies has resulted in new prospects with regard to designing more specific and effective immunotherapeutic strategies for the management of cancer patients. 11, 12 Considerable attention has been dedicated to cytokine genes, with particular emphasis on the IL-2 gene. 13 Clinically, the aim of this approach is to vaccinate patients with tumor cells induced to secrete "constitutively" and continuously low amounts of a given cytokine. The doses of cytokine released over time, while being too low to produce systemic side effects, could activate and expand cytotoxic cells capable of multiplying, recirculating, and reaching residual neoplastic cells in their different anatomic sanctuaries. This strategy has already proven effective for different tumors and with various cytokine genes in both animal and human models. 14 -19 In human melanoma, in particular, the immunogenicity of IL-2 and IL-7 gene-transduced neoplastic cells has been compared. 20 Should the cytokine gene transfer-mediated generation of specific cytotoxic effectors against tumor cells be documented also with human acute leukemias, the possibility of treating minimal residual disease with cytokine-releasing leukemic cells as a vaccine would deserve further investigation.
We have reported previously that the IL-2 gene can be successfully transduced into human leukemic cell lines of both myeloid and lymphoid origin. 21 Insertion of the IL-2 gene does not modify the phenotype and growth pattern in vitro, whereas the tumorigenic potential of an IL-2 gene-transduced T-lymphoblastic cell line could be abrogated in immunosuppressed nude mice. 21 This lymphoblastic T-cell line, ST4, has been obtained from a patient who is currently alive and in complete remission of disease. 22 The availability of the patient's lymphocytes represented a unique opportunity to assess in an autologous setting the immunogenic potential of acute leukemia cells transduced with the IL-2 and IL-7 genes.
In the present study, we have thus evaluated the cellular immune response against this T-lymphoblastic cell line by stimulating in vitro the patient's lymphocytes with autologous leukemic cells engineered to constitutively release IL-2, IL-7, or both cytokines after retroviral vector-mediated gene transfer. The immunogenicity of IL-2 gene-transduced cells (in our experimental system, transfer of the IL-7 gene did not prove effective) has been compared with that of parental cells added with different amounts of exogenous IL-2. We show that the human leukemic ST4 cells engineered to release IL-2 are capable of inducing in long-term cultures with both autologous and allogeneic lymphocytes an anti-leukemic activity that is mediated initially by major histocompatibility complex (MHC)-unrestricted effectors and subsequently by the generation of MHC class I-restricted cytolytic lymphocytes.
MATERIALS AND METHODS

Cell lines
Cell lines were cultured in RPMI 1640 supplemented with 2 mM of L-glutamine, 100 U/mL of penicillin, 100 g/mL of streptomycin (complete RPMI), and 10% of heat-inactivated fetal bovine sera (FBS) (HyClone, Cramlington, Neb). All cultures were maintained at 37°C in a 5% CO 2 humidified atmosphere. K562 and Raji cell lines were obtained from the American Type Culture Collection (Manassas, Va). ST4 is a T-lymphoblastic cell line obtained from a boy with a T-cell lymphoma; 22 the patient is currently in long-lasting (Ͼ13 years) complete remission. After retroviral vector-mediated IL-2 and IL-7-IL-2 gene transfer (see below), the bulk-infected ST4 cell lines were subcloned by limiting dilution by plating 0.3 cells/well. Clones were then expanded in complete RPMI with 10% FBS and screened for cytokine production. All cultures were regularly tested for mycoplasma.
Retroviral vector and transduction of leukemic cells
IL-2 cDNA was obtained from normal human peripheral blood lymphocytes (PBLs) and inserted into the retroviral vector LXSN, 23 which carries the neomycin resistance gene under the transcriptional control of the simian virus 40 promoter. This retroviral vector, named LXSN-IL-2, was introduced by lipofection into the AM12 amphotropic packaging cell line. 24 A supernatant with a virus titer of 6 ϫ 10 6 colony-forming units/mL was used for the infection. Human IL-7 cDNA 25 was inserted as a BamHI to BamHI fragment into the encephalomyocarditis virus (EMCV) hydromycin-thymidine kinase (HyTK) internal ribosome entry site (IRES) vector, which carries the hygromycin resistance gene under the transcriptional control of the TK promoter, to obtain the EMCV-IL-7 HyTK IRES vector. 26 The retroviral vector was introduced by electroporation into the 2 packaging cell line 27 and the transient supernatant was used to infect the PA317 packaging cell line. Supernatants from the individual colonies of producer cells resistant to hygromycin were tested for their viral titer. Supernatant from a colony with a viral titer of 2.2 ϫ 10 5 colony-forming units/mL was used for infection. To establish bulk-infected cell lines, viral supernatant was added to washed parental ST4 cells in the presence of polybrene (8 g/mL). To obtain double transfectants carrying both the IL-7 and IL-2 genes, an ST4/IL-7 bulk-infected cell line was established as described above and then infected again with a viral supernatant containing the LXSN-IL-2 vector. After infection, cell lines were selected by the appropriate drug (i.e., G418 for IL-2 transfectants, hygromycin for IL-7 transfectants, and both for IL-7-IL-2 transfectants), and the bulk-infected cultures were tested for the presence of IL-2 and/or IL-7 mRNA by reverse transcriptase polymerase chain reaction (data not shown) and for lymphokine production using bioassays and immunoassays (see below). A control retroviral vector carrying the neomycin resistance gene but no cytokine gene was used as a control of retroviral infection. Because ST4 cells infected with the control vector behave identically to the parental unmodified cell line in mixed lymphocyte-tumor cultures (MLTCs), only the results obtained with the naive ST4 cell line are reported.
Cytokine determination assays
Except when otherwise specified, leukemic cells or cells from MLTCs (see below) were seeded in complete RPMI along with 10% FBS or 10% human AB sera, respectively, at a concen-tration of 1 ϫ 10 6 /mL; supernatants were collected 72 hours later. The release of IL-2 in the culture supernatants of IL-2 gene-transduced ST4 cells was determined using both a bioassay and an immunoassay. For the bioassay, 28 peripheral blood mononuclear cells (PBMCs) from healthy donors were isolated by Lymphoprep (Nycomed, Oslo, Norway) centrifugation and cultured for 3 days in RPMI 1640 plus 10% FBS plus 1% phytohemagglutinin-M (Life Technologies, Milan, Italy). The cells were then washed and cultured for 3 additional days in RPMI 1640 plus 10% FBS plus 10% Lymphocult T (Biotest, Dreieich, Germany). These cells (known as cultured T cells (CTCs)) are very sensitive to IL-2, and their growth is IL-2-dependent. CTCs were plated at a concentration of 5 ϫ 10 4 /well in 96 U-bottom wells in the presence of decreasing amounts of IL-2 to perform a standard curve or in the presence of the supernatants to be tested and cultured for 48 hours. CTCs were then pulsed with 37 kBq of [ 3 H]thymidine/well (specific activity 5Ci/mmol; Amersham International, Buckinghamshire, UK) and harvested 18 hours later. The filters were then counted in a liquid scintillation beta counter, and the mean counts per minute of triplicate determinations were calculated. The CTC proliferation in response to serial dilutions of IL-2 was compared with that induced by supernatants to directly determine IL-2 concentrations. The IL-7 biological activity was also determined by the capability of the various supernatants to induce the proliferation of an IL-7-dependent pre-B murine cell line, PA-B clone5 (PA-B#5). 29 One unit of activity was defined as the amount of IL-7 capable of inducing 50% maximal proliferation of PA-B#5 cells. This pre-B clone is not sensitive to IL-2; on the contrary, the CTCs used in the IL-2 bioassay were also capable of proliferating in response to IL-7. To discriminate between IL-2 and IL-7 production in the IL-7-IL-2 double transfectants and to confirm the data obtained with the bioassays for the single transfectants, enzyme-linked immunosorbent assay kits for IL-2 and IL-7 were used to test all of the supernatants (both kits were a kind gift of Dr. D. De Groote, Medgenix Diagnostics, Fleurus, Belgium). Transforming growth factor-␤1 (TGF-␤1) production by ST4 parental and retrovirally engineered cells was also determined using an enzyme-linked immunosorbent assay kit (Genzyme Diagnostic, Cambridge, Mass). Because serum supplements for tissue culture may contain TGF-␤1, an appropriate tissue culture fluid control was run in the assay, as suggested by the manufacturer.
MLTC
MLTCs were established with living parental or IL-2, IL-7, and IL-7-IL-2 gene-transduced ST4 cells as stimulators (S) and autologous or allogeneic peripheral blood mononuclear cells as responders (R), at an R/S ratio of 20:1. These culture conditions were found to be optimal on the basis of preliminary experiments with allogeneic lymphocytes from healthy donors and with irradiated or living ST4 gene-transduced cells, indicating that (a) living stimulator cells are required to give an adequate stimulus in terms of both antigen and lymphokine delivery to responder cells (due to the marked radiosensitivity of ST4 cells) and (b) long-term cultures are needed to observe the spontaneous decline of natural killer (NK) activity, which never takes place before 3 weeks of culture (data not shown).
PBMCs were separated from heparinized blood by centrifugation on a Lymphoprep gradient and suspended in complete RPMI along with 10% heat-inactivated AB human sera. Autologous or allogeneic PBMCs were seeded in 25-cm 2 tissue culture flasks or in 24-well plates at a concentration of 1 ϫ 10 6 /mL and used as responder cells. Nonirradiated, replicating leukemic cells were added at a concentration of 50 ϫ 10 3 /mL to obtain an R/S ratio of 20:1. In some experiments with parental ST4 as the stimulator, exogenous IL-2 was added daily at the indicated concentrations (Chiron Corporation, Emeryville, Calif).
The percentage of living stimulator cells in the cultures was evaluated by double or triple immunofluorescence staining with the following monoclonal antibodies (mAbs): CD7, CD3, and CD56. The ST4 cell line, in fact, expresses a thymic cortical phenotype (i.e., CD1a
Ϫ , and CD16 Ϫ ) (Dako, Glostrup, Denmark; Becton Dickinson, Mountain View, Calif). When triple fluorescence was performed, a CD3 mAb conjugated with an energy transfer fluorochrome consisting of the Cyanin 5 (Cy5) dye coupled to R-phycoerythrin was used (Dako). Light energy is absorbed at 488 nm by R-phycoerythrin, transferred to Cy5, and emitted at 670 nm. Samples were stained according to standard procedures and analyzed using a FACScan flow cytometer (Becton Dickinson). When the percentage of stimulator cells was Յ3%, the different MLTCs were restimulated with their stimulator at an R/S ratio of 10:1; this procedure was repeated every 3-5 days. The cytotoxic assay was also performed only when the leukemic cells in the cultures were Յ3%.
51
Cr release assay Target cells were incubated with 50 Ci Na 2 51 CrO 4 (DuPont Products, Boston, Mass) for 1 hour at 37°C and washed. Thereafter, 2 ϫ 10 3 viable target cells were incubated with effector cells from MLTCs at different effector to target ratios for 4 hours at 37°C. After incubation, supernatants were collected and radioactivity was measured on a gamma-counter. Spontaneous release was determined by harvesting the supernatant of target cells incubated in the absence of effector cells, and maximum release was determined by resuspending target cells incubated in the absence of effector cells. The percentage of specific lysis was calculated as follows: ([experimental release Ϫ spontaneous release]/[maximum release Ϫ spontaneous release]) ϫ 100%. The spontaneous release always ranged between 5% and 20% of the total label incorporated by the cells. To determine class I restriction in the recognition of target cells (ST4 cells do not express class II), blocking studies were performed. A mouse mAb to class I (W6/32, kindly provided by Dr A. Anichini, Istituto Tumori, Milan, Italy) was added to 51 Cr-labeled targets 30 minutes before the assay at a final concentration of 10 g/mL. An antibody of the same isotype was used as a negative control. The antibodies were not washed out before mixing target and effector cells.
Statistical analysis
The statistical significance of the data was determined using a two-tailed Student's t test; P values of Ͻ.05 were considered significant.
RESULTS
IL-2 and IL-7 gene transfer and production in the ST4 T-lymphoblastic cell line Using the retroviral vector LXSN-IL-2, the IL-2 gene was introduced into the DNA of the leukemic T-cell line ST4. The bulk-infected culture, which resulted in an IL-2 production of 15 international units (IU)/mL/10 6 cells/72 hours, was cloned by limiting dilution; subclones that released variable amounts of IL-2 were obtained. Three IL-2-producing clones were used in subsequent experiments: ST4/IL-2#A7, ST4/IL-2#E7, and ST4/IL-2#E11, which released 105, 82, and 40 IU/mL/10 6 cells/72 hours of IL-2, respectively. The levels of biologically active IL-2 released daily in 1 mL of culture supernatant by plating 50 ϫ 10 3 transduced cells were also measured together with cell growth (Fig 1) . This evaluation was carried out in MLTC experiments with living tumor cells (see below) to compare the antitumor activity obtained with the IL-2 released by the engineered cells with the activity obtained with the same amounts of IL-2 added exogenously.
Using the EMCV-IL-7 HyTK IRES vector, the IL-7 gene was transduced into parental ST4 cells. After selection in hygromycin, bulk-infected cultures resulted in an IL-7 production of 16 ng/mL/10 6 cells/72 hours. The ST4/IL-7 bulk-infected cell line was transduced again with the LXSN-IL-2 retroviral vector. The bulkinfected cell line, which was capable of growing in both G418-and hygromycin-containing medium, produced 16 ng/mL/10 6 cells/72 hours of IL-7 and 10 IU/mL/10 /mL leukemic cells of clone ST4/IL-2#A7 were plated in 24-well plates; supernatants were harvested every day from different individual wells, and IL-2 production evaluated using a bioassay. Proliferation was assessed daily as the number of viable cells by trypan blue exclusion count under a light microscopy. Data represent the mean Ϯ SD of three independent experiments. Ⅺ, number of viable cells; E, IL-2 production.
higher number of leukemic cells (R/S ratio of 10:1 or 5:1) were required to sustain lymphocyte survival. Alternatively, tumor cells continued to proliferate when the stimulator was represented by ST4/IL-2#E11, a clone which produced 40 IU/mL/10 6 cells/72 hours of IL-2, or by parental ST4 cells, both alone and in the presence of exogenous amounts of IL-2 similar to the doses produced daily by equivalent numbers of ST4/IL-2#A7 cells (as shown in Fig 1) . Under these culture conditions, tumor overgrowth was observed after 8 -10 days (Fig  2A) . Thereafter, even the addition of high-dose exogenous IL-2 (100 U/mL/die), from day 8 up to day 16 was incapable of restraining leukemic proliferation. A progressive death of ST4 cells was, instead, observed when higher doses of exogenous IL-2 (20 U/mL) were added daily to the culture. Under these latter conditions, the kinetic pattern of ST4 cells was identical with that of ST4/IL-2#A7 cells (Fig 2A) . A total of 10 U/mL of IL-2 added daily to MLTCs with parental ST4 as the stimulator was incapable of restraining leukemic proliferation (data not shown).
The behavior in MLTC of the IL-7-and IL-7-IL-2-producing cell lines differed from that of the highest IL-2-producing clone, ST4-IL-2#A7. As shown in Figure 2B , only a delay in leukemic growth was observed under all IL-7 conditions, both alone and in association with IL-2, compared with the growth of the parental cell line. This delay was more pronounced in the presence of clone ST4/IL-7-IL-2#A9, the highest IL-7-producing clone, which showed a leukemic overgrowth and a complete clearance of lymphocytes only after day 60. Interestingly, none of the IL-7/IL-2-producing clones released Ͼ50 IU/mL/10 6 cells/72 hours of IL-2, confirming that IL-2 production over a certain threshold is required in the first days of the culture to block leukemic proliferation.
Similar MLTC experiments were also set up with allogeneic lymphocytes from three different donors. In all cases, the results were superimposable to those observed with autologous lymphocytes. In view of the MLTC results, the data reported below refer almost exclusively to experiments carried out with IL-2 genetransduced ST4 cells. Table 1 shows the phenotypic profile of the lymphocytes generated in autologous and allogeneic MLTCs stimulated with ST4/IL-2#A7. At the beginning of the MLTC, the patient's PBLs had a reversed CD4/CD8 ratio, with 33 Ϯ 5% CD4 ϩ , 49 Ϯ 2% CD8 ϩ , and 7 Ϯ 1% CD56 ϩ cells (mean Ϯ SD of three independent evaluations). In the intermediate days of the autologous MLTC (i.e., at day 18), CD4 ϩ cells were 18 Ϯ 3%, CD8 ϩ cells were 73 Ϯ 5%, and CD56 ϩ cells were 27 Ϯ 6%. At the end of the cultures, a population consisting of 31 Ϯ 7% CD4 ϩ , 56 Ϯ 10% CD8 ϩ , and 10 Ϯ 3% CD56 ϩ lymphocytes was observed. In allogeneic MLTCs, the initial number of CD8 ϩ was lower compared with that of autologous MLTCs and the expansion of this subset was more evident, starting from 24 Ϯ 5% at day 0 (mean Ϯ SD of three experiments with different donors), rising to 71 Ϯ 10% in the intermediate days, and concluding at 64 Ϯ 6% at the end of the MLTC. This value does not differ significantly from the final number of CD8 ϩ lymphocytes recovered at the end of the autologous MLTC. The only striking difference between the autologous and allogeneic setting was the number of CD56 ϩ in the intermediate days of the MLTC, which in the allogeneic cultures was significantly higher than in the autologous conditions (59 Ϯ 9% versus 27 Ϯ 6%, P Ͻ .01). This is paralleled by the high degree of nonspecific cytotoxic activity observed in the intermediate days of the allogeneic MLTC (see below).
Phenotype of lymphocytes generated in MLTC
Generation of cytotoxic activity in IL-2-stimulated MLTCs
The cytotoxic activity of lymphocytes generated in MLTC with different conditions of stimulation was evaluated in a 4-hour 51 Cr-release assay against unmodified stimulator cells (i.e., parental ST4 cells). Inhibition experiments with a mAb recognizing the ␣ 3 domain of the MHC class I molecule and an assessment of cytotoxic activity against the NK-susceptible target K562 and against the NK-resistant target Raji were also included. The assays were performed at different times of culture. Figure 3 shows the monitoring of the cytotoxic activity against parental ST4 and ST4 plus anti-class I mAb generated in autologous and allogeneic MLTCs with ST4/IL-2#A7 as the stimulator. In the autologous setting, the lytic activity against parental ST4 was 55% at day 21 and remained unmodified at day 35. MHCrestricted lysis against ST4 cells increased over time: blocking experiments revealed that the inhibition recorded with the anti-class I mAb W6/32 was statistically significant at the end of the culture (50 Ϯ 5.5% versus 22 Ϯ 2.5% lysis, P ϭ .0013) but not at day 21 (55 Ϯ 6% versus 44.5 Ϯ 4.5% lysis, P ϭ .072). Effector lymphocytes generated in allogeneic MLTC after 21 days of cultures showed levels of cytotoxic activity against ST4 that were higher than those obtained in autologous MLTC; this activity was mainly MHC-unrestricted as measured by anti-class I blocking (80 Ϯ 10.5% versus 64 Ϯ 8% lysis; P ϭ .1). At the end of the cultures, however, the lytic activity obtained in allogeneic MLTC (45 Ϯ 6% versus 19 Ϯ 2.5% lysis, P ϭ .0022) was superimposable to that obtained in autologous MLTC. Figure 4 shows a comparative evaluation of the cytotoxic activity recorded at the end of all MLTCs, after a mean of 35 days of culture. The NK activity against K562 was still present in all conditions, but was markedly lower compared with the activity generated against the specific stimulator ST4. Raji cells were very poorly killed, confirming the absence of lymphokine-activated killer (LAK) activity in the MLTC, even in the condition stimulated with a high total amount of IL-2 (i.e., cultures with 20 U/mL daily of exogenous IL-2). In all three culture conditions, a significant degree of inhibition was obtained after incubation of the target with an anti-MHC class I mAb (P Յ .02 in all pairs of data). Taken together, the data shown for Figure 4 indicate that the cytotoxic activities obtained under different IL-2 stimulation conditions are superimposable.
TGF-␤1 production by transduced cells
Previous studies with different retroviral vectors have demonstrated that the productive insertion of the IL-2 gene induced no change in the morphology, phenotype, and proliferative behavior of ST4 cells. 21 The cytokine gene expression of engineered ST4 cells, which was evaluated by reverse transcriptase polymerase chain reaction, was also superimposable to that of parental cells: cytokine genes that were not constitutively expressed in parental cells were not induced in transduced cells, whereas genes that were constitutively present, such as tumor necrosis factor-␤ and TGF-␤1, remained unmodified (Ref. 21 and data not shown). Given the documented immunosuppressive action of TGF-␤1 30 -32 and the capacity of only high IL-2-producing ST4 clones to generate autologous and allogeneic antitumor effectors, we also evaluated the production of TGF-␤1 by IL-2 and IL-7 gene-transduced cells compared with parental cells. Whereas parental ST4 cells released 428 Ϯ 36 pg/mL/10 6 cells/72 hours of TGF-␤1 and ST4/IL-7 released 352 Ϯ 12 pg/mL/10 6 cells/72 hours, the TGF-␤1 production by ST4/IL-2#A7 and ST4/IL-2#E7 was below the sensitivity level of the kit (Ͻ100 pg/mL/10 6 cells/72 hours) (mean value of three different samples collected separately). Clone ST4/IL-2#E11 released 295 Ϯ 30 pg/mL/10 6 cells/72 hours of TGF-␤1. In another set of experiments, supernatants from six ST4/ IL-7-IL-2 clones were tested. A notable reduction in TGF-␤1 release was observed only with clones producing Ͼ30 IU/mL/10 6 cells/72 hours of IL-2. As predicted by the absence of both the ␣-and ␤-chains of the IL-2 receptor, 21 exogenous IL-2 added at different doses (10, 100, and 1000 U/mL) 24 or 72 hours before supernatant harvesting did not modulate TGF-␤1 production in parental ST4 cells.
DISCUSSION
The main purpose of this work was to investigate the immunogenicity of cytokine gene-transduced human leukemic cells. We took advantage of a T-lymphoblastic cell line (ST4) generated from a living patient, which allowed us to perform lymphocyte-tumor cocultures in an autologous setting. The results of experiments carried out in MLTC with engineered leukemic cells as a stimulator indicate that through the continuous release of low (but above a well-defined threshold) amounts of IL-2, the in vitro death of leukemic cells may be induced in both autologous and allogeneic culture conditions. Similar results could not be achieved with leukemic cells transduced with the IL-7 gene.
Based on the IL-2 released by the different clones used in our experiments (including also the IL-7/IL-2-producing clones), we were able to demonstrate that clones producing Ͻ50 IU of IL-2 were incapable of blocking the initial leukemic growth and, consequently, of generating cytotoxic effectors over time. This effect was not observed with similar doses of exogenous IL-2 added daily, thus pointing to the superiority of the IL-2 constitutively released by the engineered cells compared with the exogenous molecule. It could be argued that 20 IU/mL daily is a relatively low dose, if translated in vivo. It should, however, be pointed out that the comparison between doses of exogenous and transduced IL-2 can be accurate only in this in vitro system. In view of the very short half-life of IL-2, the in vivo administration of exogenous IL-2 as a "selective adjuvant" for vaccination protocols is likely to require much higher amounts of this cytokine to achieve the same biological result obtained with the continuous release in the cell to cell milieu.
The observations that the percentage of leukemic cells in both autologous and allogeneic MLTCs fell from 50 -60% to 10 -20% within 4 days, from day 4 to day 8 of culture, and that the cytotoxic activity against ST4 was still mainly nonspecific at day 21 underline the role of NK-like effectors, when properly stimulated, in mediating the initial clearing of leukemic cells from the cultures. This was further confirmed by the expansion of 
CD56
Ϫ cell populations were incapable of restraining leukemic proliferation (data not shown). Subsequently, starting from day 21, this NK-like activity started to decline, together with the percentage of CD56 ϩ cells; at the same time, the cytotoxic activity specifically directed against unmodified ST4 cells increased, representing the majority of the total activity by the end of the MLTC.
The constitutive production of IL-7, alone or in combination with IL-2 (at lower levels compared with clones producing high levels of IL-2 alone), by the retrovirally engineered leukemic cells did not prove effective in the generation of anti-leukemic cytotoxic effectors in MLTC. Even if a possible role for IL-7 in synergy with a higher IL-2 dose cannot be ruled out, our results demonstrate the crucial role of IL-2, compared with IL-7, in the generation of anti-leukemic effectors with cytokine gene-transduced tumor cells. The greater immunogenic potential of the highest IL-2-producing clones could also be contributed by the marked decrease in TGF-␤1 production compared with parental ST4 cells. It is well documented that TGF-␤1, which is produced constitutively by tumor cells of different origin, [33] [34] [35] may impair both the NK 30 and LAK activity, 31 as well as inhibit the generation of specific cytotoxic T lymphocytes in autologous MLTCs. 32 Because ST4 cells do not express the ␣-and ␤-chains of the IL-2 receptor, it was to be expected that exogenous IL-2 could not decrease TGF-␤1 production in parental ST4 cells. The observation that down-modulation of TGF-␤1 production occurs in high IL-2-producing clones, and not in clones producing lower levels of IL-2 or in IL-7-transduced cells, points to a specific role of given amounts of endogenously produced IL-2 in mediating this effect, probably through some unknown intracellular pathway, as already postulated. 36 Although the possibility of activating MHC-restricted cytotoxic effectors against T leukemic blasts (only through high-dose exogenous IL-2) has already been Blocking with anti-class I mAb was statistically significant in all three pairs of data (55 Ϯ 5% versus 31 Ϯ 3% lysis for autologous lymphocytes plus ST4 plus 20 IU/mL/die IL-2, P ϭ .002; 50 Ϯ 5.5% versus 22 Ϯ 2.5% lysis for autologous lymphocytes plus ST4/ IL-2#A7, P ϭ .0013; 45 Ϯ 6% versus 19 Ϯ 2.5% lysis for allogeneic lymphocytes plus ST4/IL-2#A7, P ϭ .0022).
documented, 37 these results demonstrate for the first time the capability of IL-2 gene-transduced lymphoblasts to generate from the PBLs of a patient in complete remission a specific, human histocompatibility leukocyte antigen (HLA)-restricted, cytotoxic response against his own unmodified blasts. In view of the lack of HLA class II expression by ST4 cells, of the HLA restriction to class I by the cytotoxic effectors, and of the increased proportion of CD8 ϩ cells in MLTCs, the major part of the specific lytic activity appears to be mediated by CD8 ϩ cytotoxic T lymphocytes. A relevant degree of nonspecific cytotoxic activity could also be induced and maintained over time under the same culture conditions: these NK-like effectors with prolonged activity, even if theoretically incapable of immune memory, could thus play a role not only in the early phases of the anti-leukemic response but also in keeping the leukemic clone under control. The results of this in vitro model help in the understanding of the clinical and long-lasting responses observed in a proportion of acute leukemia patients with residual bone marrow blasts treated with IL-2 alone. 2, 5 In the latter patients, the protocol contemplated up to four courses of high-dose IL-2, followed by a prolonged "maintenance" schedule with low-dose IL-2 given monthly for 5 days. Based on the findings hereby reported, it is likely that the early and more pronounced anti-leukemic action is exerted largely by MHC-unrestricted cytotoxic effectors, as documented by the enhancement of NK and LAK activity described in the treated patients, 6, 7 whereas maintenance IL-2 administration may further contribute to disease control via the progressive "education" of MHC-restricted anti-leukemic lytic effectors, as well as via the protracted action of nonrestricted cytotoxic effectors. Two important implications can be derived from these findings: (a) the presence of a detectable proportion of blasts in patients treated with IL-2 may be important to promote an adequate immune stimulation, and (b) the empirically designed, prolonged maintenance IL-2 administration appears to have a biological basis.
Taken together, these results suggest that the vaccination protocols with IL-2 gene-transduced neoplastic cells recently activated for different solid tumors 38 may also have a preclinical rationale in acute leukemia. In view of the potential role of engineered leukemic cells as therapeutic vaccines hereby documented, the issue of transducing primary acute leukemia blasts will need to be carefully addressed. We have attempted to transduce growth factor-stimulated primary leukemic blasts with the same IL-2 vector used in this study, but have so far failed to achieve detectable levels of cytokine production, despite the presence of the IL-2 mRNA in the transduced cells. Although expression of the costimulatory molecule CD80 in primary acute myeloid leukemia blasts has been demonstrated using a different retroviral vector, 39 adenoviral, adeno-associated, lentiviral vectors or newly generated retroviral vectors need to be explored to obtain a satisfactory level of cytokine release by primary human leukemic cells. 40 -45 
